Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

The Novavax vaccine should work against variants b

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154078
(Total Views: 506)
Posted On: 11/22/2021 2:32:26 PM
Avatar
Posted By: Drano
Re: JLang #110858
The Novavax vaccine should work against variants because it includes proteins from the BODY of the virus. Those proteins are unchanging or else it wouldn't be the COVID virus.

Also, Novavax's technology does not use the entire spike. It uses protein segments from the spike. Therefore, if a mutation occurs on one section of the spike, the vaccinee's immune system should still recognize the unchanged protein portions from the spike.

This is not the mRNA technology. It is based on the older technologies.

Whether it lasts longer remains to be seen.

It's unfortunate that there has been NO publicity on how the FDA screwed Novavax, by taking away their manufacturing ability by decertifying the contract plant they were using -- then, the same day, re-certifying it for Pfizer. Then, when Novavax found a plant in South Korea that was already certified for other manufacturing, the FDA refused to send an inspector for months. THAT is why Pfizer and Moderna were first out of the box with vaccines, instead of Novavax, which could have had their vaccine approved first if not for the FDA.

And that's why NVAX has been submitting applications and getting contracts worldwide -- Japan, New Zealand, UK, EU, Canada, various Latin American and African and Asian countries -- but has not submitted to the U.S. FDA. They say, maybe, by the end of the year, maybe.

Who can blame them for going where they know they'll be approved first, and then the weight of public opinion will FORCE the FDA to approve.


(8)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us